Browsing Tag
Sarepta Therapeutics
14 posts
Dyne Therapeutics (NASDAQ: DYN) slides as $375m stock sale resets valuation
Dyne Therapeutics strengthens launch funding, but its discounted $375 million share sale tests whether regulatory progress can outrun dilution pressure.
Why the FDA’s warning on Elevidys matters for Duchenne muscular dystrophy treatment
Sarepta’s Elevidys gene therapy now carries an FDA boxed warning. Find out what it means for Duchenne patients, investors, and gene therapy safety.
Sarepta Therapeutics (NASDAQ: SRPT) hit by FDA boxed warning as ELEVIDYS loses non‑ambulatory DMD indication
Sarepta’s ELEVIDYS gene therapy label now includes a boxed liver warning and removes non-ambulatory DMD use. Explore the safety updates and investor outlook.
Vinay Prasad returns to top FDA post amid political whiplash and gene therapy fallout
Dr. Vinay Prasad has been reinstated as Chief Medical and Scientific Officer at the U.S. FDA just weeks after stepping down. His reappointment is reshaping biotech regulatory dynamics and reviving questions about scientific independence under political pressure.
Sarepta Therapeutics awards 25 Route 79 scholarships in 2025–2026, but what makes this Duchenne program unique?
Sarepta Therapeutics awarded 25 Route 79 scholarships for 2025–2026 to support students impacted by Duchenne. See how this initiative strengthens community ties.
Sarepta Therapeutics halts ELEVIDYS shipments for non-ambulatory Duchenne patients as FDA demands enhanced safety measures
Sarepta Therapeutics halts ELEVIDYS shipments for non-ambulatory Duchenne patients amid FDA liver safety review; analysts assess market risks and future outlook.
Sarepta’s gene therapy marches on: UK clears continued dosing in Duchenne Phase 3 trial
Find out how Sarepta Therapeutics is advancing Duchenne gene therapy with UK backing for its ENVISION trial of ELEVIDYS in non-ambulatory patients.
U.S. stock market selloff: Alphabet, Sarepta, Lantheus lead broad decline amid trade tensions and economic headwinds
See why top U.S. stocks including Alphabet, Sarepta, Lantheus, and Marvell tumbled on May 7 amid rising trade tensions and economic uncertainty.
Sarepta, Palantir, Moderna lead Wall Street declines as biotech, tech stocks tumble
U.S. stock market losers on May 6, 2025: Find out why Sarepta, Palantir, Moderna, Lattice Semiconductor and more saw sharp stock price drops.
US stock market declines as Vaxcyte, Biohaven, and Moderna lead losses
US stocks closed sharply lower on March 31, 2025, led by biotech and tech losses. Learn why markets are reacting to tariffs, interest rates, and economic uncertainty.